

Health Technology Assessment: Role in technology development & use

FIONA A. MILLER, PhD

ASSOCIATE PROFESSOR OF HEALTH POLICY, IHPME

DIRECTOR, DIVISION OF HEALTH POLICY & ETHICS, THETA

Health Loss & Health Aging,
IOM-NRC Workshop
Washington, DC
January 14, 2014



Institute of Health Policy, Management & Evaluation
UNIVERSITY OF TORONTO



theta


Toronto Health Economics and
Technology Assessment Collaborative


“Explore innovative hearing technologies, and barriers to their development and use”

- Health Technology Assessment (HTA) – barrier & facilitator
 - Applied policy analysis to support decisions about payment for health technologies (including drugs, devices, diagnostics, procedures, etc..)
 - Evidence-informed
 - Value-laden
- Plays important and growing role in determining use
- Increasingly organized to support technology development



Out-of-Pocket Spending as a Percentage of Total Health Expenditures, Select Countries, 2008





Kaiser Permanente Triangle

Source: UK Department of Health (2005)



Institute of Health Policy, Management & Evaluation
UNIVERSITY OF TORONTO



theta

Toronto Health Economics and
Technology Assessment Collaborative

HTA INFLUENCING USE



Institute of Health Policy, Management & Evaluation
UNIVERSITY OF TORONTO




theta

Toronto Health Economics and
Technology Assessment Collaborative

HTA

- Multidisciplinary field of applied policy analysis
 - Emerged in US
 - Well developed internationally
 - International Network of Agencies for HTA (INAHTA) now includes 57 member agencies from 32 countries



Institute of Health Policy, Management & Evaluation
UNIVERSITY OF TORONTO



Newly Approved Does Not Always Mean New and Improved

Geoffrey M. Anderson,
David Juurlink,
Allan S. Detsky,

PHARMACOLOGICAL
to make
new pro
judgment
for innovation in
tion is the basis of
The most pro
“blockbuster” dr
that generate mo
lective inhibitor
atypical antipsy



Institute of Health Economics and
UNIVERSITY OF TORONTO

HT Regulation:

- Is it safe to have this technology on the market – at least for a specific class of patients?
- Does it – in theory – do what it claims to do?

HT Assessment:

- Is it safe and at least as good as alternatives – in the real world?
- Is it worthwhile to invest in this technology?

al symptoms of
never been ap-
need, use of these
for a large pro-

t of patients with
ntly for the treat-
ap with those of
drugs (NSAIDs).
prescribing in-
AIDs decreased
s and coxibs far
one.⁵ These new
they seemed to
nts treated with



HTA: Variable role in healthcare systems

- Detached from coverage
 - CADTH
 - Many European HTA agencies
- Directly informing coverage (eg, baskets of insured goods)
 - NICE, UK
 - OHTAC, CED, Ontario, Canada
- Directly informing priority setting (eg, services provided in closed budget environments)
 - Hospital/ regional-based HTA



Doing HTA

Clinical evidence

- Safety & efficacy
- Real world effectiveness
- Comparative effectiveness



Doing HTA

Clinical evidence

- Safety & efficacy
- Real world effectiveness
- Comparative effectiveness

Economic evidence

- Value for money (cost utility, value-based pricing)
- Budget impact/ affordability



Doing HTA

Clinical evidence

- Safety & efficacy
- Real world effectiveness
- Comparative effectiveness

Economic evidence

- Value for money (cost utility, value-based pricing)
- Budget impact/ affordability

Patient & social values

- Patient preferences
- Health equity
- Accountability for reasonableness



HTA

INFLUENCING DEVELOPMENT



Institute of Health Policy, Management & Evaluation
UNIVERSITY OF TORONTO



theta

Toronto Health Economics and
Technology Assessment Collaborative

- Innovation policy
 - Increased attention to “demand side” among governments
 - Procurement chief instrument
 - Some attention to health
- Health policy
 - Health care systems as ‘drivers of growth’
 - UK: NHS
 - “Accelerating adoption and diffusion”

INNOVATION HEALTH AND WEALTH

ACCELERATING ADOPTION AND DIFFUSION IN THE NHS



Institute of Health Policy, Management & Evaluation
UNIVERSITY OF TORONTO



Toronto Health Economics and
Technology Assessment Collaborative

HTA experiments 1.

- HTA & adoption
 - NICE, UK
 - Health Technologies Adoption Programme
 - Aligned with Medical Tech Assessment
 - Support med tech industry in UK
 - OHTAC, Ontario
 - Implementation Framework
 - Health technology value chain



Institute of Health Policy, Management & Evaluation
UNIVERSITY OF TORONTO

NICE National Institute for Health and Care Excellence

Home | News | Get involved | About NICE

Find guidance | NICE Pathways | Quality standards | Into practice | QOF

Home > News > News > NICE boosts support for innovative ideas

News

- News archive
- Media centre
- Features
- NICE newsletters and alerts
- Events
- NICE annual conference
- Guidance in Focus
- Podcasts
- Videocasts
- Meetings held in public

NICE boosts support for innovative ideas

NICE's support for hospitals wanting to adopt innovative new technologies has been given a boost as it takes on the work of the NHS Technology Adoption Centre (NTAC) in May.

With funding from NHS England, the new Health Technologies Adoption Programme (HTAP) at NICE will provide a more systematic approach to the adoption by the NHS of new technologies such as diagnostic and monitoring devices, surgical implants and other technologies that improve the care given to patients.

Despite the often considerable potential of these new technologies to improve patient health and increase NHS productivity, there is concern that the benefits are not made available to patients quickly enough. The government's Innovation Health and Wealth report in 2011 recommended the transfer of the NHS Technology Adoption Centre to NICE in an effort to improve uptake.

NICE's new programme will work in a similar way to NTAC, engaging with front-line clinicians, managers and procurement specialists in hospitals, clinical commissioning groups and community services to enable them to better understand and overcome the barriers to adoption.

The team of five have already been working closely with NICE's Medical Technologies Programme, supporting the implementation of products that have been evaluated by NICE. By moving into the

Ontario
Health Quality Ontario
Qualité des services
de santé Ontario

Implementation Subcommittee
Report on the Gap between
Evidence and Uptake

HTA experiments 2.

- HTA & harmonization
 - Exploring harmonization of regulatory and HTA requirements
 - Exploring consistency/ clarity on HTA/ coverage requirements

International Journal of Technology Assessment in Health Care, 27:3 (2011), 253–260.
© Cambridge University Press 2011
doi:10.1017/S0266462311000262

POLICIES

Interactions between health



ALZHEIMER'S DISEASE PILOT

The Green Park Collaborative (GPC) is an international initiative exploring the scientific and procedural feasibility of developing guidance for the life science industry on the design of clinical studies to meet the needs of HTA and coverage bodies. The outputs of the pilot include an [Evidence Guidance Document on Alzheimer's Disease](#), and an [evaluation of the pilot process](#). The prototype guidance document is not intended to represent consensus statements on the part of its participants, but rather demonstrate the feasibility of and inform the subsequent development of guidance beyond the pilot phase.

GPC-INTL is jointly led by:



www.htai.org

University of Oslo and Norwegian Knowledge Center for the Health Services

On behalf of the HTAi Policy Forum



Institute of Health Policy, Management & Evaluation
UNIVERSITY OF TORONTO

HTA experiments 3.

- ‘Early’ HTA
 - “Decision-support” for industry
 - Public demand as “sophisticated customers”
 - MaRS-EXCITE, Ontario
 - Single, harmonized, pre-market, evidence-analysis and evidence-generation process



HTA: Technology use & development

- Growing & increasingly demanding role for HTA
 - Supporting evidence-informed & value laden resource allocation decisions
 - More actively engaging with role in innovation system
- Analysis of merits of collective investments in hearing loss technologies
- Guide/incentive for development of further technological innovations relevant to hearing loss



Health Technology Assessment: Role in technology development & use

FIONA A. MILLER, PhD

ASSOCIATE PROFESSOR OF HEALTH POLICY, IHPME

DIRECTOR, DIVISION OF HEALTH POLICY & ETHICS, THETA

Health Loss & Health Aging,
IOM-NRC Workshop
Washington, DC
January 14, 2014



Institute of Health Policy, Management & Evaluation
UNIVERSITY OF TORONTO



theta

Toronto Health Economics and
Technology Assessment Collaborative